Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study by Eijkelboom, Anouk H. et al.






The following full text is a publisher's version.
 
 





Please be advised that this information was generated on 2021-11-01 and may be subject to
change.
Eijkelboom et al. J Hematol Oncol           (2021) 14:64  
https://doi.org/10.1186/s13045-021-01073-7
RESEARCH
Impact of the COVID-19 pandemic 
on diagnosis, stage, and initial treatment 
of breast cancer in the Netherlands: 
a population-based study
Anouk H. Eijkelboom1, Linda de Munck1, Marie‑Jeanne T. F. D. Vrancken Peeters2,3, Mireille J. M. Broeders4,5, 
Luc J. A. Strobbe6, Monique E. M. M. Bos7, Marjanka K. Schmidt8, Cristina Guerrero Paez9, 
Marjolein L. Smidt10,11, Maud Bessems12, Janneke Verloop1, Sabine Linn13,14, Marc B. I. Lobbes11,15,16, 
Aafke H. Honkoop17, Desirée H. J. G. van den Bongard18, Pieter J. Westenend19, Jelle Wesseling13,20, 
C. Willemien Menke‑van der Houven van Oordt21, Vivianne C. G. Tjan‑Heijnen22 and Sabine Siesling1,23*  on 
behalf of the NABON COVID‑19 Consortium and the COVID and Cancer‑NL Consortium 
Abstract 
Background: The onset of the COVID‑19 pandemic forced the Dutch national screening program to a halt and 
increased the burden on health care services, necessitating the introduction of specific breast cancer treatment rec‑
ommendations from week 12 of 2020. We aimed to investigate the impact of COVID‑19 on the diagnosis, stage and 
initial treatment of breast cancer.
Methods: Women included in the Netherlands Cancer Registry and diagnosed during four periods in weeks 2–17 of 
2020 were compared with reference data from 2018/2019 (averaged). Weekly incidence was calculated by age group 
and tumor stage. The number of women receiving initial treatment within 3 months of diagnosis was calculated by 
period, initial treatment, age, and stage. Initial treatment, stratified by tumor behavior (ductal carcinoma in situ [DCIS] 
or invasive), was analyzed by logistic regression and adjusted for age, socioeconomic status, stage, subtype, and 
region. Factors influencing time to treatment were analyzed by Cox regression.
Results: Incidence declined across all age groups and tumor stages (except stage IV) from 2018/2019 to 2020, par‑
ticularly for DCIS and stage I disease (p < 0.05). DCIS was less likely to be treated within 3 months (odds ratio  [OR]wks2–8: 
2.04,  ORwks9–11: 2.18). Invasive tumors were less likely to be treated initially by mastectomy with immediate reconstruc‑
tion  (ORwks12–13: 0.52) or by breast conserving surgery  (ORwks14–17: 0.75). Chemotherapy was less likely for tumors diag‑
nosed in the beginning of the study period  (ORwks9–11: 0.59,  ORwks12–13: 0.66), but more likely for those diagnosed at 
the end  (ORwks14–17: 1.31). Primary hormonal treatment was more common  (ORwks2–8: 1.23,  ORwks9–11: 1.92,  ORwks12–13: 
3.01). Only women diagnosed in weeks 2–8 of 2020 experienced treatment delays.
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Background
The COVID-19 pandemic still has the world in its grip. 
In the Netherlands, the first COVID-19 cases were iden-
tified at the end of February 2020 in the south of the 
country [1]. The virus then spread gradually across the 
country, affecting mainly southern and central regions. 
From the second week of March, societal measures were 
introduced, such as social distancing, closing schools, 
and urging people to stay at home as much as possible. 
A key driver of this policy was to protect the most vul-
nerable in society, such as the elderly and the chronically 
ill. In addition to having wide reaching effects on soci-
ety, health care services switched focus to patients with 
COVID-19, thereby generating pressures on all other 
health care domains. Efforts were made to ease the bur-
den on health care services overwhelmed by the surge 
of COVID-19 patients, to reallocate personal protective 
equipment to health care staff tackling COVID-19, and to 
mitigate the spread of COVID-19.
The Dutch breast cancer screening program invites 
women aged 50–74  years for biennial screening mam-
mography. However, in line with efforts to prioritize care 
for COVID-19, national screening programs were halted 
from March 16, 2020 (week 12), including that for breast 
cancer. Combined with the decreased number of refer-
rals from general practitioners (GPs) [2], this has led to 
a drop in the number of breast cancer diagnoses in the 
Netherlands [3]. To accommodate the many changes 
brought about by COVID-19, the Dutch Society of Medi-
cal Oncology (NVMO), the Dutch Society of Surgical 
Oncology (NVCO), and the Dutch Society of Radiother-
apy and Oncology (NVRO) collaborated to issue recom-
mended treatment strategies to be applicable from week 
12 (Additional file  1: Table  1) [4]. These recommenda-
tions had three goals: 1) to continue safe and effective 
oncological care for all new and known patients; 2) to 
decrease the risk of infection for patients and staff; and 
3) to ensure the availability of protective materials, staff, 
and intensive care unit capacity for critically ill patients 
with COVID-19.
In April 2020, the multidisciplinary National Breast 
Cancer Organization of the Netherlands (NABON) 
established its NABON COVID-19 Consortium to moni-
tor, evaluate, and learn from the impact of COVID-19 on 
breast cancer care. This is the first study performed by 
this consortium and seeks to report on the impact of the 
COVID-19 pandemic on the incidence of breast cancer 




Women older than 18  years and diagnosed with breast 
cancer during weeks 2–17 of 2018, 2019, or 2020 were 
selected for inclusion from the Netherlands Cancer 
Registry (NCR). The NCR is hosted by the Netherlands 
Comprehensive Cancer Organization (IKNL) and has 
records of all newly diagnosed malignancies notified 
by the Nationwide Histopathology and Cytopathology 
Data Network and Archive (PALGA) since 1989. Within 
3  months after breast cancer diagnosis, the following 
data are gathered: patient characteristics (e.g., age at 
diagnosis, gender, socioeconomic status [SES]), detec-
tion method (e.g., screening), tumor characteristics (e.g., 
TNM stage, morphology, grade, and hormone receptor 
status), and primary treatment (e.g., surgery, neoadju-
vant therapy, and systemic therapy). Data collection is 
completed 9 months after diagnosis by including further 
details on adjuvant and other treatments.
The present study was approved by the Privacy Review 
Board of the NCR and data were made available until 
week 17, 2020. We analyzed data on the diagnosis and 
initial treatment (i.e. within the first 3 months after diag-
nosis) of breast cancer patients.
Definitions
Weeks 2–17 of 2020 were considered the “COVID-19 
period” and were divided into four: period A to cover 
weeks 2–8 (i.e., before the COVID-19 pandemic); period 
B, weeks 9–11 (i.e., between the first COVID-19 case and 
the social lockdown); period C, weeks 12–13 (i.e., the 
lockdown was introduced and screening was halted); and 
period D, weeks 14–17 (i.e., referrals from the screening 
program ended). We included averaged data for weeks 
2–17 of 2018 and 2019 as a reference.
Tumors were grouped by their method of detection 
(screening or symptomatic presentation). Age at diag-
nosis was grouped into ages < 40, 40–49, 50–64, 65–74, 
and > 74 years. SES was determined based on the patient’s 
postal code at the time of diagnosis. Hormone recep-
tor (HR) and human epidermal growth factor receptor 
2 (HER2) status were combined in the variable “tumor 
subtype,” as follows: HR+/HER2+, HR+/HER2−, HR−/
HER2+, and HR−/HER2−. Stage (ductal carcinoma 
Conclusion: The incidence of breast cancer fell in early 2020, and treatment approaches adapted rapidly. Clarification 
is needed on how this has affected stage migration and outcomes.
Keywords: COVID‑19, Breast cancer, Incidence, Screening, Treatment, Stage, Population‑based
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in situ [DCIS] and stage I, II, II, IV) was defined accord-
ing to the TNM staging system [5]. Patients were also 
categorized into one of the five regions (provinces) in the 
Netherlands where they were diagnosed: the north (Gro-
ningen, Friesland, Drenthe), the middle east (Overijssel, 
Flevoland), the middle (Gelderland, Utrecht), the west 
(Noord-Holland, Zuid-Holland, Zeeland), and the south 
(Limburg, Noord-Brabant).
Statistical analysis
All data were analyzed using Stata version 16.1 software 
(StataCorp, College Station, Texas, USA). The baseline 
characteristics of participants diagnosed in weeks 2–17 
of either 2018/2019 or 2020 are presented descriptively. 
Chi-squared tests were used to compare patients diag-
nosed in periods A, B, C, and D of 2020 with those diag-
nosed in the same periods for 2018/2019. A two-sided p 
value < 0.05 was considered statistically significant. Inci-
dence and treatment data were then compared in detail.
The incidence of newly diagnosed breast tumors was 
calculated for each week and expressed per 1 million 
women living in the Netherlands at the start of the year 
using data from Statistics Netherlands (CBS) [6]. To cal-
culate the number of potentially missed breast cancers 
diagnoses, the incidence of DCIS and of invasive breast 
cancer in weeks 9–17 of 2020 was subtracted from the 
average incidence of DCIS and of invasive cancer in 
weeks 9–17 of 2018/2019. This was then divided by 1 
million and multiplied by 8,759,554 (i.e., the number of 
women living in the Netherlands at the start of 2020). 
The mean decrease in incidence (min–max) per indi-
vidual hospital in weeks 9–17 of 2020 was calculated as a 
percentage of the number of diagnoses in weeks 9–17 of 
2018/2019.
The incidence of newly diagnosed screen-detected and 
non-screen-detected tumors, expressed per 1 million 
women aged 50–74  years living in the Netherlands at 
the start of the year, was determined for each week. The 
average incidence per week was calculated for periods A, 
B, C, and D of 2020 and for the corresponding weeks in 
2018/2019 by age group, tumor stage, and region. Inci-
dences were also expressed per 1 million women of a 
given age group living in the Netherlands at the start of 
the year. The incidence in each period of 2020 was com-
pared with the average for the same period in 2018/2019 
using STATA’s iri command with a midp-calculation [7]. 
A one-sided p value of < 0.05 was considered statistically 
significant because we expected a decline in breast can-
cer diagnoses. The average number of patients hospital-
ized with COVID-19 per week was calculated per period 
for each region to reflect the severity of the outbreak, 
using data from the National Institute for Public Health 
and Environment [1].
The number of women receiving an initial treatment 
within 3 months after diagnosis, out of the average num-
ber of women diagnosed per week, was calculated. Data 
were stratified by period (weeks 2–17 of 2018/2019, and 
periods A, B, C, and D of 2020) and type of initial treat-
ment. Initial treatment included no treatment, breast 
conserving surgery (BCS), mastectomy with immediate 
breast reconstruction (IBR), mastectomy without IBR, 
chemotherapy (with or without targeted therapy), hor-
monal therapy, and other initial therapy (e.g., targeted 
therapy only, radiotherapy, and metastasis-directed radi-
otherapy). Data were further stratified by tumor stage and 
age group. Initial treatments during the four COVID-19 
periods were compared with those given during the ref-
erence period using the Mantel–Haenszel test. Analyses 
were adjusted for tumor stage or age group, depending 
on the stratification variable. When heterogeneity was 
present, age groups and tumor stages were analyzed sep-
arately. A two-sided p value of < 0.05 was deemed statisti-
cally significant for these analyses.
Logistic regression was performed to calculate the odds 
ratios and 95% confidence intervals (CIs) for the associa-
tion between diagnosis period and chance of receiving a 
certain treatment as initial treatment. Analyses were per-
formed per initial treatment and tumor behavior (DCIS 
or invasive). For patients with invasive cancers, the asso-
ciation between diagnosis period and time (in days) from 
diagnosis to initial treatment was determined by Cox 
proportional hazard models estimating hazard ratios and 
95%CIs. Analyses were performed per initial treatment, 
were only patients who received the treatment of interest 
were included. Both analyses were adjusted for age group, 
SES, region, subtype, and stage. A two-sided p value 
of < 0.05 was deemed statistically significant. No analysis 
was performed for delay in treatment for DCIS because 
this was recommended (Additional file 1: Table 1).
Results
The characteristics of patients diagnosed in weeks 2–17 
of 2018 and 2019 were comparable (Additional file  1: 
Table 2), with 5685 and 5838 patients diagnosed, respec-
tively. By contrast, 4769 patients were diagnosed in the 
same period of 2020 (Table  1). The absolute number of 
breast cancer diagnoses decreased most prominently 
in period D for patients aged 50–64 or 65–74  years 
(p < 0.01); moreover, the absolute numbers of DCIS and 
stage I tumor diagnoses fell most in period D (p < 0.01).
Incidence
The incidence of breast cancer started to decline from 
week 9, with an even steeper decline from week 11. 
Breast cancer incidence reached its nadir in week 14, 
after which it started to increase again from week 17 
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Table 1 Baseline characteristics by diagnosis period
Data are reported as N (%) of patients diagnosed in weeks 2–17 of 2018/2019 or 2020
The p value was calculated on known values only, using the chi-square test to compare patients diagnosed in weeks 2–8, 9–11, 12–13, or 14–17 of 2020 with those 
diagnosed in the same period from the average for the years 2018 and 2019
DCIS, ductal carcinoma in situ; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; SES, socioeconomic status
a The average was taken over 2018 and 2019
Weeks 2–8 Weeks 9–11 Weeks 12–13 Weeks 14–17
2018/2019a 2020 p 2018/2019a 2020 p 2018/2019a 2020 p 2018/2019a 2020 p
Patients 2547.5 2692 1074.5 995 737.5 436 1402 646
Age
 < 40 129.5 (5.1) 142 (5.3) 0.02 51 (4.8) 44 (4.4) 0.55 36.5 (5.0) 19 (4.4) 0.42 54 (3.9) 64 (9.9) < 0.01
 40–49 389.5 (15.3) 372 (13.8) 158.5 (14.8) 128 (12.9) 104.5 (14.2) 62 (14.2) 204.5 (14.6) 111 (17.2)
 50–64 912.5 (35.8) 898 (33.4) 387.5 (36.1) 368 (37.0) 266.5 (36.1) 175 (40.1) 524.5 (37.4) 200 (31.0)
 65–74 674 (26.5) 771 (28.6) 284.5 (26.5) 282 (28.3) 206.5 (28.0) 121 (27.8) 358 (25.5) 118 (18.3)
 > 74 442 (17.4) 509 (18.9) 193 (18.0) 173 (17.4) 123.5 (16.8) 59 (13.5) 261 (18.6) 153 (23.7)
SES
 High 782.5 (30.7) 788 (29.3) < 0.01 295.5 (27.5) 316 (31.8) 0.04 211.5 (28.7) 133 (30.5) 0.47 410.5 (29.3) 206 (31.9) 0.28
 Medium 992.5 (39.0) 1169 (43.4) 421 (39.2) 379 (38.1) 282.5 (38.3) 153 (35.1) 569.5 (40.6) 242 (37.5)
 Low 763.5 (30.0) 719 (26.7) 355 (33.0) 298 (30.0) 239.5 (32.5) 148 (33.9) 413.5 (29.5) 193 (29.9)
 Unknown 9 (0.4) 16 (0.6) 3 (0.3) 2 (0.2) 4 (0.5) 2 (0.5) 8.5 (0.6) 5 (0.8)
Morphology
 DCIS 309 (12.1) 352 (13.1) 0.44 119.5 (11.1) 125 (12.6) 0.33 79.5 (10.8) 65 (14.9) 0.03 178 (12.7) 42 (6.5) 0.00
 Invasive ductal 1761.5 ( 69.2) 1828 (67.9) 756 (70.4) 671 (67.4) 504.5 (68.4) 294 (67.4) 951 (67.8) 480 (74.3)
 Invasive lobular 342.5 (13.4) 380 (14.1) 135 (12.6) 141 (14.2) 122 (16.5) 55 (12.6) 198 (14.1) 92 (14.2)
 Other 134.5 (5.3) 132 (4.9) 64 (6.0) 58 (5.8) 31.5 (4.3) 22 (5.1) 75 (5.4) 32 (5.0)
Stage
 DCIS 309 (12.2) 352 (13.2) 0.25 119.5 (11.1) 125 (12.6) 0.69 79.5 (10.8) 65 (15.0) 0.09 178 (12.7) 42 (6.6) < 0.01
 Stage I 1044.5 (41.1) 1075 (40.4) 446 (41.6) 418 (42.2) 306 (41.6) 167 (38.6) 559.5 (40.0) 212 (33.1)
 Stage II 828.5 (32.6) 891 (33.5) 358 (33.4) 316 (31.9) 247 (33.6) 142 (32.8) 473.5 (33.8) 269 (42.0)
 Stage III 233.5 (9.2) 211 (7.9) 97 (9.0) 82 (8.3) 72 (9.8) 35 (8.1) 122 (8.7) 64 (10.0)
 Stage IV 128 (5.0) 134 (5.0) 52 (4.9) 49 (5.0) 31 (4.2) 24 (5.5) 66.5 (4.8) 54 (8.4)
Subtype
 HR+/HER2+ 210 (8.2) 171 (6.4) 0.01 74.5 (6.9) 64 (6.4) 0.88 48.5 (6.6) 30 (6.9) 0.59 111.5 (8.0) 62 (9.6) 0.12
 HR+/HER2– 1678 (65.9) 1743 (64.8) 717 (66.7) 657 (66.0) 510 (69.2) 286 (65.6) 921.5 (65.7) 428 (66.3)
 HR−/HER2+ 83 (3.3) 65 (2.4) 41.5 (3.9) 33 (3.3) 30 (4.1) 11 (2.5) 42 (3.0) 30 (4.6)
 HR−/HER2− 249 (9.8) 275 (10.2) 112 (10.4) 98 (9.9) 64.5 (8.8) 35 (8.0) 137.5 (9.8) 76 (11.8)
 Unknown 327.5 (12.9) 438 (16.3) 129.5 (12.1) 143 (14.4) 84.5 (11.5) 74 (17.0) 189.5 (13.5) 50 (7.7)
Region
 North 257.5 (10.1) 254 (9.4) 0.02 111.5 (10.4) 99 (10.0) 0.74 74 (10.0) 46 (10.6) 0.17 135 (9.6) 71 (11.0) 0.86
 Middle East 230.5 (9.1) 257 (9.6) 98.5 (9.2) 97 (9.8) 71.5 (9.7) 55 (12.6) 123.5 (8.8) 59 (9.1)
 Middle 488 (19.2) 589 (21.9) 214 (19.9) 208 (20.9) 139 (18.9) 94 (21.6) 297.5 (21.2) 132 (20.4)
 West 1010.5 (39.7) 991 (36.8) 406 (37.8) 384 (38.6) 304.5 (41.3) 165 (37.8) 538 (38.4) 246 (38.1)
 South 560.5 (22.0) 600 (22.3) 244.5 (22.8) 207 (20.8) 148.5 (20.1) 76 (17.4) 308 (22.0) 138 (21.4)
Screened
 Yes 810 (31.8) 837 (31.1) 0.87 354.5 (33.0) 342 (34.4) 0.43 256.5 (34.8) 172 (39.5) 0.12 455.5 (32.5) 12 (1.9) 0.00
 No 727.5 (28.6) 762 (28.3) 299 (27.8) 275 (27.6) 201.5 (27.3) 107 (24.5) 403.5 (28.8) 282 (43.7)
 Not eligible 961 (37.7) 1023 (38.0) 402.5 (37.5) 345 (34.7) 264.5 (35.9) 140 (32.1) 519.5 (37.1) 328 (50.8)
 Unknown 49 (1.9) 70 (2.6) 18.5 (1.7) 33 (3.3) 15 (2.0) 17 (3.9) 23.5 (1.7) 24 (3.7)
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(Fig.  1). Fewer patients (150 DCIS and 1000 invasive 
tumors) were diagnosed after week 9 in 2020 compared 
with 2018/2019. At the hospital level, the mean decrease 
in breast cancer diagnoses during weeks 9–17 was 33.5% 
in 2020, ranging from an increase of 32.1% to a decrease 
of 87.3%. Within the 50–74 year age group, the incidence 
of screen-detected tumors started to drop from week 12 
onwards, when screening was temporarily halted, and 
reached almost zero in week 14. The incidence of non-
screen-detected tumors dropped from week 11 onwards, 
reaching its nadir in week 14, after which it increased 
again in week 17 (Fig. 2).
Fig. 1 Incidence of breast cancer per week. Incidence is expressed per 1 million women living in the Netherlands at the start of the year. *The week 
only includes four working days due to public holidays
Fig. 2 Incidence of screen‑ and non‑screen‑detected tumors per week. Incidence is expressed per 1 million women aged 50–74 years living in the 
Netherlands at the start of the year. *The week only includes four working days due to public holidays. ‡The week only includes on average four and 
a half working days due to public holidays in 2018
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Compared with the same periods in 2018/2019, 
breast cancer incidence fell significantly in all age cat-
egories in period C and D, except in patients younger 
than 40  years (Fig.  3). In period B, the incidence of 
stage II tumors fell significantly, while in period C, the 
incidence of stage I, II, and III tumors fell significantly. 
The incidence of all tumors, except stage IV, also fell 
significantly in period D (Fig. 4). Finally, breast cancer 
incidence fell significantly in all regions except the mid-
dle east of the Netherlands in period C and fell signifi-
cantly in all regions in period D (Fig. 5).
Fig. 3 Average weekly incidence, per 1 million women of that specific age category, stratified by period. Incidence is expressed per 1 million 
women of that specific age category living in the Netherlands at the start of the year. *The incidence in that period is significantly lower compared 
to the average incidence in the same period of 2018/2019 (p < 0.05)
Fig. 4 Average weekly incidence of different stage tumors, per 1 million women, stratified by period. Incidence is expressed per 1 million women 
living in the Netherlands at the start of the year. *The incidence in that period is significantly lower compared to the average incidence in the same 
period of 2018/2019 (p < 0.05)
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Treatment
Treatment differences are summarized in Table 2. Com-
pared with 2018/2019, the proportions diagnosed with 
DCIS in periods A and B of 2020 and not treated within 
3  months of diagnosis increased by 7.3% and 8.6%, 
respectively. The proportion of stage II tumors in period 
B receiving chemotherapy within 3 months fell by 10.0%. 
By contrast, the proportional use of hormonal therapy 
increased by 19.2% for stage IV tumors in period C and 
by 5.6% for stage I tumors in period D; use also increased 
among patients aged > 74  years by 23.9% in period C 
(Additional file 1: Table 3). Concerning BCS, the propor-
tion of stage I tumors treated in period D fell by 14.9%. 
Finally, the proportion of patients aged 50–64  years in 
period D who received chemotherapy increased by 16.0%.
After adjusting for age group, SES, and region, there 
was a greater odds of DCIS diagnosed in period A or 
B not being treated within 3 months of diagnosis com-
pared with the reference period (Table 3). In addition, 
after adjusting for age group, SES, subtype, stage and 
region, patients diagnosed with an invasive tumor in 
period A, B, or, C of 2020 were more likely to receive 
hormonal treatment initially. The odds of receiving 
chemotherapy were lower for patients diagnosed in 
period B or C, while the odds of undergoing mastec-
tomy with IBR was lower in period C. In period D, the 
odds of undergoing BCS were lower and the odds of 
receiving chemotherapy were higher.
There was a longer interval between diagnosis and 
initial treatment in period A compared with the refer-
ence period for patients with invasive tumors receiving 
BCS, mastectomy without IBR, or hormonal treatment 
(Additional file  1: Table  4). By contrast, shorter inter-
vals were seen for those in period B receiving either 
mastectomy with IBR or hormonal treatment, as well 
as for those in period C receiving BCS, mastectomy 
with/without IBR, or hormonal treatment. The median 
time from diagnosis to initial treatment in the refer-
ence period was 27  days (interquartile range (IQR): 
20–36) compared with 29 days (IQR: 21–40; p < 0.001) 
in period A, 22  days (IQR: 14–31, p < 0.001) in period 
C, and 25 days (IQR: 18–35, p < 0.001) in period D.
Fig. 5 Average weekly incidence and average weekly number of hospitalized COVID‑19 patients per region and period. Breast cancer incidence is 
expressed per 1 million women living in that specific region of the Netherlands at the start of the year. *The incidence in that period is significantly 
lower compared to the average incidence in the same period of 2018/2019 (p < 0.05)
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Table 2 Women per week by initial treatment within 3 months of diagnosis, diagnosis period, and stage
Data are shown as average n (%). We compared data for weeks 2–17, 2020 (the COVID-19 period) with those for weeks 2–17, 2018/2019 using the Mantel–Haenszel 
test, adjusted by age (< 40, 40–50, 50–65, 65–74, > 74 years)
The arrows show statistically significant data corrected for age: ↑ = more patients received this therapy; ↓ = fewer patients received this therapy
BCS, breast conserving surgery; DCIS, ductal carcinoma in situ; IBR, immediate breast reconstruction; Mx, mastectomy; wk, week
Analyses stratified per age group was performed and significant differences are explained:
a Lower proportion of patients 65–74 years old with DCIS received BCS
b Higher proportion of patients 65–74 years old with DCIS received hormonal treatment
c Higher proportion of patients < 40 years old with stage I received mastectomy with IBR
d Higher proportion of patients 50–74 years old with stage I or stage II received hormonal treatment
e Higher proportion of patients < 75 years old with stage I received hormonal treatment
f Higher proportion of patients 40–74 years old with stage II received hormonal treatment
g Higher proportion of patients < 50 years old or > 74 years old with stage II received hormonal treatment
h Higher proportion of patients < 40 years old with stage III received chemotherapy
i Higher proportion of patients < 50 years old or 65–74 years old with stage III received hormonal treatment
j Higher proportion of patients < 40 years old with stage IV received chemotherapy
k Higher proportion of patients 40–49 years old with stage IV received chemotherapy
l Higher proportion of patients aged < 40 years old or 50–64 years old with stage IV received chemotherapy
m Higher proportion of patients 40–49 years old or 65–74 years old with stage IV received hormonal treatment
Total Untreated BCS Mx with IBR Mx without IBR Chemotherapy Hormonal treatment Other
DCIS
 2018/2019, wk 2–17 42.8 3.9 (9.1) 27.9 (65.2) 5.0 (11.8) 5.4 (12.6) 0.2 (0.4) 0.4 (0.9) 0.0 (0.2)
 2020, wk 2–8 49.7 8.1 (16.4) ↑ 29.7 (59.8) 5.1 (10.3) 6.4 (12.9) 0.1 (0.3) 0.1 (0.3) 0.0 (0.0)
 2020, wk 9–11 41.3 7.3 (17.7) ↑ 22.7 (54.8) 3.7 (8.9) 7.0 (16.9) 0.0 (0.0) 0.7 (1.6) 0.0 (0.0)
 2020, wk 12–13 32.0 3.5 (10.9) 19.5 (60.9)a 2.0 (6.3) 5.5 (17.2) 0.0 (0.0) 1.5 (4.7)b 0.0 (0.0)
 2020, wk 14–17 9.8 1.0 (10.3) 4.5 (46.2) 2.0 (20.5) 1.8 (17.9) 0.3 (2.6) 0.3 (2.6) 0.0 (0.0)
Stage I
 2018/2019, wk 2–17 147.0 2.7 (1.8) 103.0 (70.1) 10.1 (6.9) 16.8 (11.4) 7.1 (4.8) 7.3 (4.9) 0.2 (0.1)
 2020, wk 2–8 153.1 2.6 (1.7) 104.6 (68.3) 8.9 (5.8)c 18.0 (11.8) 9.1 (6.0) 9.9 (6.4) 0.1 (0.1)
 2020, wk 9–11 138.7 1.7 (1.2) 95.0 (68.5) 10.0 (7.2) 17.7 (12.7) 2.3 (1.7) ↓ 12.0 (8.7)d 0.0 (0.0)
 2020, wk 12–13 83.5 1.0 (1.2) 55.5 (66.5) 3.5 (4.2) 9.5 (11.4) 3.0 (3.6) 11.0 (13.2)e 0.0 (0.0)
 2020, wk 14–17 52.5 0.8 (1.4) 29.0 (55.2) ↓ 4.8 (9.0) 7.5 (14.3) 5.0 (9.5) ↑ 5.5 (10.5) ↑ 0.0 (0.0)
Stage II
 2018/2019, wk 2–17 119.1 2.6 (2.2) 36.3 (30.5) 5.3 (4.5) 20.9 (17.6) 37.5 (31.5) 16.0 (13.4) 0.4 (0.4)
 2020, wk 2–8 127.1 2.9 (2.2) 35.9 (28.2) 5.9 (4.6) 21.7 (17.1) 38.7 (30.4) 21.9 (17.2)f 0.3 (0.2)
 2020, wk 9–11 105.3 3.3 (3.2) 32.0 (30.4) 3.3 (3.2) 20.0 (19.0) 22.7 (21.5) ↓ 24.0 (22.8)d 0.0 (0.0)
 2020, wk 12–13 71.0 1.0 (1.4) 22.5 (31.7) 1.5 (2.1) 10.5 (14.8) 20.0 (28.2) 15.5 (21.8)g 0.0 (0.0)
 2020, wk 14–17 66.0 1.0 (1.5) 17.3 (26.1) 2.0 (3.0) 12.3 (18.6) 22.5 (34.1) 11.0 (16.7) 0.0 (0.0)
Stage III
 2018/2019, wk 2–17 32.7 0.8 (2.6) 2.0 (6.2) 0.6 (1.8) 5.9 (18.1) 17.5 (53.6) 5.3 (16.2) 0.5 (1.4)
 2020, wk 2–8 29.9 1.1 (3.8) 2.4 (8.1) 0.4 (1.4) 6.0 (20.1) 14.4 (48.3) 5.4 (18.2) 0.0 (0.0)
 2020, wk 9–11 27.3 0.3 (1.2) 1.3 (4.9) 0.3 (1.2) 5.3 (19.5) 14.0 (51.2)h 6.0 (22.0) 0.0 (0.0)
 2020, wk 12–13 17.5 0.0 (0.0) 0.5 (2.9) 1.5 (8.6) ↑ 2.5 (14.3) 6.0 (34.3) 7.0 (40.0)i 0.0 (0.0)
 2020, wk 14–17 15.5 0.3 (1.6) 0.8 (4.8) 1.0 (6.5) ↑ 2.3 (14.5) 9.3 (59.7) 2.0 (12.9) 0.0 (0.0)
Stage IV
 2018/2019, wk 2–17 17.2 1.6 (9.3) 0.3 (2.0) 0.0 (0.2) 0.6 (3.5) 5.7 (33.3) 7.4 (43.3) 1.5 (8.5)
 2020, wk 2–8 19.1 3.1 (16.4) ↑ 0.4 (2.2) 0.0 (0.0) 0.9 (4.5) 6.3 (32.8) 7.4 (38.8) 1.0 (5.2)
 2020, wk 9–11 16.3 2.0 (12.2) 0.7 (4.1) 0.0 (0.0) 0.7 (4.1) 5.3 (32.7)j 7.7 (46.9) 0.0 (0.0)
 2020, wk 12–13 12.0 1.0 (8.3) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 3.5 (29.2)k 7.5 (62.5) ↑ 0.0 (0.0)
 2020, wk 14–17 13.5 1.5 (11.1) 0.0 (0.0) 0.0 (0.0) 0.3 (1.9) 5.8 (42.6)l 5.3 (38.9)m 0.8 (5.6)
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Discussion
As expected, we found that the incidence of breast cancer 
started to decline after the social lockdown and the tem-
porary pause in screening at week 12. This decrease was 
seen in all age groups and all regions, and it was unre-
lated to the severity of the COVID-19 outbreak based 
on the number of patients hospitalized with COVID-19. 
The incidence of stage IV tumors did not decline. There 
was also a clear change in initial treatment received by 
patients diagnosed during the outbreak period, with 
fewer undergoing either BCS or mastectomy plus IBR, 
and more receiving primary hormonal treatment. More-
over, the interval between diagnosis and initial treatment 
decreased compared with 2018/2019.
The fall in breast cancer incidence was greatest among 
patients aged 50–74 years, consistent with those eligible 
for screening, when screening programs were tempo-
rarily halted from week 12. The increased reluctance of 
patients to visit their GP and the lack of capacity at GPs 
was reflected by the decrease in incidence across all age 
groups. Similarly, the decline in incidence among patients 
aged ≥ 75  years in weeks 12–13 may have reflected the 
advice that the vulnerable (e.g., the elderly and people 
with chronic diseases), stay at home.
Given that screening detects most DCIS (72%) and 
stage I tumors (64%) [8], we anticipated that the tem-
porary cessation of screening would cause these stages 
to have the greatest decrease in incidence. Patients with 
suspicious lesions detected at screening are normally 
referred to hospital within 2 weeks, meaning that weeks 
12–13 still reflected patients with DCIS referred from 
screening, and explaining the delayed decrease from 
week 14. The incidence of stage II tumors had already 
started to decline in weeks 9–11, but unlike the early 
stage tumors, only 38% of these are typically detected 
by screening. In this instance, the earlier decline in inci-
dence may reflect reluctance to visit a GP despite symp-
toms/complaints or a lack of capacity at GPs. By contrast, 
given that only 9% of stage IV tumors are detected by 
screening and present with worrisome symptoms that are 
unlikely to be ignored, it was unsurprising that their inci-
dence did not decrease.
Despite the north of the Netherlands being least 
affected by COVID-19, we found no regional differ-
ences in diagnosis rates or treatment strategies between 
regions. This reflects the national impact of the meas-
ures. The increase in incidence in week 17 likely reflects 
the national call by official authorities in weeks 14 and 15 
to visit a GP when experiencing symptoms. The national 
screening program restart only began in mid-June and 
could not have influenced the incidence.
Specific Dutch recommendations mentioned that 
treatment can be delayed for DCIS (Additional file  1: 
Table 1). The COVID-19 Pandemic Breast Cancer Con-
sortium (CPBCC) also recommended delaying surgery 
for patients with DCIS, while the European Society for 
Medical Oncology (ESMO) gave the lowest priority to 
surgery for DCIS (except for high-grade DCIS) [9, 10]. 
Our results reflect the implementation of these recom-
mendations. Although research has shown that delaying 
surgery for up to 60  days did not negatively affect dis-
ease-free survival or nodal status in patients with DCIS 
[11], other research has shown that a greater delay to sur-
gery is associated with a greater risk of finding invasive 
cancer [12]. It has also been reported that 21% of patients 
diagnosed clinically with DCIS appear to have an invasive 
Table 3 Association between diagnosis period and type of initial treatment
Logistic regression calculating the odds ratios and 95% confidence intervals to investigate the association between period of diagnosis of the tumor (week 2–17 
2018/2019 as a reference) and type of initial treatment, for DCIS and invasive tumors separately
BCS, breast conserving surgery; DCIS, ductal carcinoma in situ; IBR, immediate breast reconstruction; Mx, mastectomy; NA, not applicable
a Odds ratios are adjusted for age groups, socioeconomic status, and region
b Odds ratios are adjusted for age groups, socioeconomic status, stage, subtype, and region
Not yet treated BCS Mx with IBR Mx without IBR Chemotherapy Hormonal treatment Other
DCISa
 Weeks 2–8 2.04 (1.44–2.88) 0.81 (0.63–1.04) 0.87 (0.58–1.32) 0.95 (0.66–1.36) 0.71 (0.08–6.32) 0.27 (0.03–2.19) NA
 Weeks 9–11 2.18 (1.31–3.61) 0.72 (0.49–1.05) 0.56 (0.28–1.10) 1.36 (0.82–2.26) NA 2.13 (0.40–11.33) NA
 Weeks 12–13 1.38 (0.61–3.13) 0.80 (0.47–1.36) 0.44 (0.15–1.29) 1.38 (0.70–2.72) NA 18.32 (3.68–91.30) NA
 Weeks 14–17 1.07 (0.37–3.11) 0.53 (0.28–1.04) 1.92 (0.78–4.74) 1.40 (0.60–3.25) 5.98 (0.57–62.65) 2.13 (0.22–20.53) NA
Invasiveb
 Weeks 2–8 1.11 (0.84–1.48) 0.93 (0.83–1.04) 0.93 (0.74–1.16) 1.01 (0.88–1.16) 0.96 (0.82–1.12) 1.23 (1.05–1.44) 0.50 (0.25–0.98)
 Weeks 9–11 0.95 (0.60–1.50) 0.93 (0.79–1.10) 0.97 (0.70–1.36) 1.11 (0.91–1.36) 0.59 (0.45–0.76) 1.92 (1.53–2.41) NA
 Weeks 12–13 0.63 (0.27–1.45) 0.91 (0.70–1.17) 0.52 (0.28–0.96) 0.90 (0.65–1.24) 0.66 (0.45–0.95) 3.01 (2.20–4.11) NA
 Weeks 14–17 0.83 (0.48–1.45) 0.75 (0.61–0.92) 1.08 (0.73–1.59) 1.11 (0.87–1.41) 1.31 (1.01–1.70) 1.26 (0.96–1.65) 0.42 (0.13–1.38)
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tumor at surgery [13]. Hence, delaying surgery might not 
be appropriate for all patients. Our research also showed 
that patients diagnosed with an invasive tumor before 
the pandemic may have experienced a delay in treat-
ment as hospitals transitioned to accommodate the new 
health care demands. Patients diagnosed with an invasive 
tumor during the COVID-19 pandemic did not experi-
ence a treatment delay and may have even been treated 
earlier, indicating successful transition to the new treat-
ment plan. Furthermore, the Dutch, the CPBCC, and the 
ESMO guidelines recommend using neoadjuvant hormo-
nal treatment for patients with HR-positive tumors [9, 
10], which we can confirm was implemented. Combining 
data from international trials, researchers have reported 
that hormonal treatment can lead to a safe delay in sur-
gery for at least 6  months in some patients (e.g., post-
menopausal, early stage, estrogen receptor-positive, and 
HER2-negative) [14].
To reduce pressure on operating room capacity and to 
lower the risk of complications after breast surgery, the 
Association of Breast Surgery and the American Society 
of Plastic Surgeons recommended avoiding IBR [15, 16], 
while ESMO give a low priority to breast reconstructions 
[10]. Although this was not specified in the Dutch rec-
ommendations, we observed a decrease in the use of IBR. 
Moreover, the ESMO guideline states that chemotherapy 
can be omitted in patients if the risk-to-benefit appraisal 
for neoadjuvant chemotherapy is uncertain, only after 
careful discussion with the patient [17]. The Dutch guide-
lines did not discourage the use of neoadjuvant chemo-
therapy, but they did recommend adjusting the doses 
or types of chemotherapy to prevent neutropenia. The 
lower use of chemotherapy at the beginning of the pan-
demic was probably related to limitations placed on hos-
pital visits and the expected increased risk of COVID-19 
complications. The decrease in patients hospitalized for 
COVID-19 after week 17 probably led to the increased 
use of chemotherapy in patients diagnosed toward the 
end of the pandemic period that we studied [1]. Hospitals 
might have decided to treat their patients with chemo-
therapy because of the lower COVID-19 risk. In the cur-
rent study, 38 patients were recorded as having clinically 
suspected COVID-19, and of these, 29% received initial 
treatment with chemotherapy.
This study, which we believe is the first of its kind, 
benefited from using data from the NCR for all women 
diagnosed with breast cancer in the Netherlands, thereby 
accurately reflecting daily practice. However, the study 
has some important limitations. First, the use of neo-
adjuvant chemotherapy has been increasing over time 
[18, 19], so the decrease in chemotherapy use during the 
COVID-19 period may be an underestimation. Second, 
we did not consider hospital transfers when calculating 
the number of patients hospitalized with COVID-19 in 
each region, although we have no reason to doubt that 
our data offer a good representation of the true burden 
of COVID-19 in each region. Third, the distribution in 
the number of diagnoses in each age category and region 
differed in weeks 2–8 between 2020 and 2018/2019, 
meaning that we cannot exclude the impact of data fluc-
tuations unrelated to the COVID-19 pandemic. As such, 
these results should be interpreted with care. Finally, 
we limited our study to the first treatment given within 
3  months of diagnosis, which neglects any changes in 
therapy or delays in adjuvant therapy. Future research 
will require a longer follow-up period to investigate the 
effects of the COVID-19 pandemic on the management 
of patients with breast cancer throughout treatment.
Conclusion
The COVID-19 outbreak, related societal measures, and 
cessation of breast cancer screening led to about 1,150 
missed cases of breast cancer. However, we found that 
this reduction mainly occurred for the lowest stage dis-
ease, and as such, it is hoped that the delay in diagnosis 
will not have had a large impact on long-term outcomes. 
Moreover, patients diagnosed after week 8 experienced 
no delays in treatment, though it was notable that initial 
treatments moved away from surgical options through-
out (e.g., BCS and mastectomy with IBR) and seemed 
to be replaced by primary hormonal treatment. Future 
studies will need to determine the long-term effects 
of both the delayed diagnosis and the changes in treat-
ment strategies on outcomes. Only then will we be able 
to make a definitive conclusion. In the meantime, there 
are three key lessons to be learned from this study: 1) it 
is important to maintain a functioning national screening 
program during a pandemic to prevent a major backlog 
in breast cancer diagnosis; 2) patients, especially those 
aged ≥ 75 years, should be encouraged to visit a GP when 
experiencing symptoms; and 3) recommendations can be 
implemented rapidly nationwide thanks to good commu-
nication and management both nationally and locally.
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